banda transcan 2 2016ul

Title: Early detection of prostate cancer by liquid biopsies

Project Coordinator:
Klaus PANTEL (Germany) University Medical Centre Hamburg Eppendorf, Hamburg

Project Partners:
Desiree BONCI (Italy) Istituto Superiore di Sanità, Rome
Catherine ALIX-PANABIÈRES (France) University Medical Centre of Montpellier, Montpellier
Evi LIANIDOU (Greece) University of Athens, Athens
Maciej ZABEL (Poland), Poznan University of Medical Sciences, Poznan

Project Abstract:
Prostate cancer (PCa) is a major cause of cancer-related mortality and morbidity in men of the western world. Standard PSA screening has a high rate of false-positive findings (up to 60%) and therefore more specific methods for early detection of PCa are urgently needed. Recently, partners of our consortium have played a key role in implementing the concept of “Liquid biopsies” (i.e., analysis of tumour cells or tumour cell-derived nucleic acids and exosomes in blood) into research on PCa (TRANSCAN project CTC-SCAN, ended in 2016) and other solid tumours (EU/IMI project CANCER-ID). The primary aim of this research proposal is to improve blood-based detection of PCa patients by testing of circulating tumor cells (CTCs), tumour-derived exosomes and circulating cell-free DNA (cfDNA) as Liquid biopsies. 
Analysing peripheral blood samples from men with elevated PSA concentrations that undergo prostate biopsy, we will stratify patients in cancer and non-cancer cohorts based on the outcome of the histological evaluation of the tissue biopsy. Cancer patients will undergo surgical resection or radiotherapy. In the first year (discovery period), we will assess which Liquid biopsy marker or combination of markers will (i) provide the best discrimination between the two cohorts and (ii) identifies in particular high-risk PCa patients with aggressive tumour as defined by a Gleason score (“gold standard”) of 8 or higher. Biobanks from former studies on PCa (e.g., CTC-SCAN) will be used in particular for plasma studies (cfDNA, exosomes). 
Candidates will be further explored in the subsequent training and validation study (years 2 and 3) in order to obtain the blood test with the highest sensitivity and specificity for detection of early PCa and/or high-risk PCa. Blood from men with elevated PSA levels (gold standard for PCa screening) will be analysed prospectively before tissue biopsy are taken to avoid biopsy-induced interference of blood results. Comparing the results of Liquid biopsy with tissue biopsy histology (gold standard for PCa diagnosis) we will identify single or bloodbased marker combination with the highest sensitivity and specificity for detection of total PCa and/or high-risk PCa. The unique combination of expertise assembled in this consortium will guarantee a complementary investigation of the relevance of Liquid biopsy for early detection of PCa at the European level.

 

 

(Project funded under JTC 2016)


TRANSCAN News

Launch of the call: JTC 2021
The new TRANSCAN-3 project consortium is launching the first Joint Transnational Call for proposals, co-funded by the European Commission, on:
"Next generation cancer immunotherapy: targeting the tumour microenvironment"

International Networking Event (virtual)
on 22 April 2021 hrs 9:00 CET
will focus on the forthcoming co-funded JTC 2021 on:
"Next generation cancer immunotherapy: targeting the tumour microenvironment" 
the event is organized by TUBITAK under the “Turkey in Horizon 2020 Phase II” Technical Assistance Project
in cooperation with TRANSCAN-3

ERA-NET Cofund TRANSCAN-3:
 Sustained collaboration of national and regional programmes in cancer research
is the new project funded by the European Commission under H2020  which started on 1st March 2021 and will last five years (G. A. no. 964264)

A TRANSCAN-2 brochure, highlighting key achievements, is available for download

 

eu flagship

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 643638.

Who's Online

We have 8 guests and no members online